LDS/Medical Tests/PDGFRA (platelet-derived growth factor receptor, alpha polypeptide) Gene Mutation Analysis

PDGFRA (platelet-derived growth factor receptor, alpha polypeptide) Gene Mutation Analysis

The PDGFRA gene is located on the long (q) arm of chromosome 4 at position 12. This gene encodes platelet-derived growth factor receptor alpha (PDGFRA) protein, which is part of a family of proteins called receptor tyrosine kinases (RTKs). PDGFRA protein binds to certain isoforms of platelet-derived growth factors (PDGFs) and thereby becomes active in stimulating cell-signaling pathways. The signaling pathways stimulated by the PDGFRA protein control many important cellular processes such as cell growth, division and cell survival. Mutations or translocations of the PDGFRA gene are associated with PDGFRA-associated chronic eosinophilic leukemia characterized by an increased number of eosinophils and gastrointestinal stromal tumors (GISTs) that is most common in the stomach or small intestine. The somatic mutation in PDGFRA gene causes a deletion of genetic material from chromosome 4 that brings together parts of two genes, FIP1L1 and PDGFRA, creating the FIP1L1-PDGFRA fusion gene. Point mutations can also cause this condition, although these mutations are seen very rarely.

Fusions of the FIP1L1 and PDGFRA genes are also found in acute myeloid leukemia with eosinophilia, T-cell lymphoblastic lymphoma with associated eosinophilia, and chronic eosinophilic leukemia. The protein produced from the FIP1L1-PDGFRA fusion gene (as well as other PDGFRA fusion genes) does not require binding of the platelet-derived growth factor protein to be activated. As a result, the signaling pathways are constantly activated, which increases the proliferation and survival of cells. Similarly, point mutations in the PDGFRA gene can result in a PDGFRA protein that is activated without ligand binding. When the FIP1L1-PDGFRA fusion gene mutation or point mutations in the PDGFRA gene occur in marrow stem cells, the growth of eosinophils (and occasionally other blood cells) is poorly controlled, leading to PDGFRA-associated chronic eosinophilic leukemia.

Typically, acquired somatic mutations in the PDGFRA gene are identified in GISTs occurring in the stomach or small intestine. Less commonly, PDGFRA gene mutations that increase the risk of developing GISTs are inherited from a parent, which can lead to familial GISTs. As in the hematologic disorders, PDGFRA gene mutations associated with GISTs create a protein that no longer requires binding of the platelet-derived growth factor protein to be activated. As a result, the PDGFRA protein and the signaling pathways are constitutively activated, which increases cell proliferation and survival, leading to tumor formation. PDGFRA gene mutations that lead to a constitutively active PDGFRA protein are also associated with inflammatory fibroid polyps, which are small, noncancerous (benign) tumors that form in the gastrointestinal tract.

  • Diagnosis and management of patients with gastrointestinal stromal tumors
  • As an aid in diagnosis of idiopathic hypereosinophilic syndrome
  • As an aid in diagnosis of PDGFRA-associated chronic eosinophilic leukemia
  • For the management of patients with PDGFRA-associated chronic eosinophilic leukemia, gastrointestinal stromal tumors or other related tumors

Positive: if mutation in PDGFRA gene or PDGFRA fusion gene detected most likely indicates neoplastic changes from the tissue tested. 

Negative: if negative for PDGFRA gene or PDGFRA fusion gene decreases risk of cancer.

Negative for mutation in PDGFRA gene or PDGFRA fusion gene

Polymerase Chain Reaction (PCR) and Next generation Sequencing.

Formalin-fixed, paraffin-embedded (FFPE) tissue block.

Stability

  • Ambient: Indefinitely
  • Refrigerated: Indefinitely
  • Frozen: Unacceptable
Electrophoresis, immunohistochemistry, H/E stain, complete blood count (CBC), Computed tomography (CT or CAT) scan, Magnetic resonance imaging (MRI) scan, Bone marrow aspiration and biopsy, Fine needle aspiration (FNA) biopsy, Excisional or incisional biopsy, Flow cytometry, CT-guided needle biopsy, PET scan, endoscopy, liver function tests, FISH, Karyotyping.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login